By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
The report pointed out that in the process of treating Covid-19, there are promising data to suggest that TCM is beneficial in reducing the risk of progression from mild-to-moderate cases to severe Covid-19
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University
The investment of around €7 million significantly enhances the site’s flexibility and capacity in synthesizing modern, complex and even corrosive molecules
Ideal power boosters to strengthen muscles and keep energised for all kinds of physical activities
The funding round is led by Kalaari Capital. Aflac Ventures, Digital Horizon, Stride Ventures, and existing investors also participated in the round
Crosscope Dx is a workflow integrated vendor-agnostic digital pathology platform that offers end-to-end digital pathology solutions with advanced workflow features
Subscribe To Our Newsletter & Stay Updated
